Affinity Investment Advisors LLC lifted its position in bluebird bio, Inc. (NASDAQ:BLUE) by 27.4% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,981 shares of the biotechnology company’s stock after acquiring an additional 642 shares during the period. Affinity Investment Advisors LLC’s holdings in bluebird bio were worth $409,000 as of its most recent SEC filing.
Several other large investors have also recently made changes to their positions in the company. Quantitative Investment Management LLC increased its position in bluebird bio by 1,193.8% during the 2nd quarter. Quantitative Investment Management LLC now owns 104,800 shares of the biotechnology company’s stock valued at $11,009,000 after buying an additional 96,700 shares in the last quarter. State of Wisconsin Investment Board bought a new position in bluebird bio during the 2nd quarter valued at approximately $3,257,000. Winfield Associates Inc. increased its position in bluebird bio by 6.1% during the 2nd quarter. Winfield Associates Inc. now owns 2,822 shares of the biotechnology company’s stock valued at $296,000 after buying an additional 162 shares in the last quarter. OMERS ADMINISTRATION Corp bought a new position in bluebird bio during the 2nd quarter valued at approximately $1,061,000. Finally, Northern Trust Corp increased its position in bluebird bio by 11.7% during the 2nd quarter. Northern Trust Corp now owns 518,673 shares of the biotechnology company’s stock valued at $54,487,000 after buying an additional 54,142 shares in the last quarter.
bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.68) by ($0.05). The company had revenue of $7.71 million during the quarter, compared to analysts’ expectations of $8.47 million. bluebird bio had a negative net margin of 883.18% and a negative return on equity of 28.79%. The company’s quarterly revenue was up 397.4% compared to the same quarter last year. During the same period in the prior year, the business posted ($2.07) earnings per share.
ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.com-unik.info/2017/11/03/affinity-investment-advisors-llc-increases-stake-in-bluebird-bio-inc-blue.html.
In other bluebird bio news, insider David Davidson sold 4,000 shares of the stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $131.31, for a total value of $525,240.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Nick Leschly sold 46,833 shares of the stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $122.27, for a total transaction of $5,726,270.91. Following the completion of the sale, the insider now owns 289,368 shares of the company’s stock, valued at approximately $35,381,025.36. The disclosure for this sale can be found here. In the last quarter, insiders sold 149,141 shares of company stock valued at $18,759,547. 3.90% of the stock is owned by insiders.
A number of research firms recently weighed in on BLUE. Jefferies Group LLC reaffirmed a “hold” rating and set a $130.00 price objective on shares of bluebird bio in a research report on Friday. BidaskClub raised bluebird bio from a “sell” rating to a “hold” rating in a research report on Wednesday, August 9th. Maxim Group reiterated a “buy” rating and set a $170.00 target price on shares of bluebird bio in a research note on Thursday. Morgan Stanley reiterated a “hold” rating on shares of bluebird bio in a research note on Wednesday, August 9th. Finally, Leerink Swann reiterated an “outperform” rating and set a $162.00 target price (up from $145.00) on shares of bluebird bio in a research note on Wednesday. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $129.45.
bluebird bio Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
What are top analysts saying about bluebird bio Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for bluebird bio Inc. and related companies.